ELOVL7

ELOVL7 is a very-long-chain fatty acid elongase that sits at the intersection of lipid metabolism, SREBP-driven transcriptional programs, and inflammatory and cell-death signaling (PMID:19826053, PMID:41285716, PMID:40940503). Its core biochemical activity is the elongation of fatty acids: in prostate cancer cells it preferentially elongates saturated very-long-chain fatty acids (C20:0 and longer), and its knockdown reduces these species in both phospholipids and neutral lipids while attenuating de novo androgen synthesis, linking ELOVL7 elongation to steroidogenesis (PMID:19826053). Substrate preference is context-dependent: in goat mammary epithelial cells ELOVL7 instead acts on unsaturated C16–C18 fatty acids (PMID:31242694). Transcriptionally, ELOVL7 is a downstream effector of SREBP — induced by androgen signaling via SREBP1 in prostate cancer (PMID:19826053), and repressed through a malate–SREBP axis by fumarate hydratase in cardiac hypertrophy, where forced ELOVL7 expression reverses the cardioprotective effect of FH (PMID:40940503). In injured podocytes, ELOVL7 upregulation drives accumulation of phospholipids bearing long-chain polyunsaturated acyl tails, raising lipid peroxidation and sensitizing cells to ferroptosis, as confirmed by podocyte-specific knockout mice (PMID:41285716). In macrophages, NF-κB-dependent ELOVL7 induction promotes IL-6 and IL-12/IL-23 p40 production, placing the enzyme within the pro-inflammatory response (PMID:37251958).

1. 2009 High

   Established the fundamental biochemical identity of ELOVL7 as an elongase with a defined substrate preference, and connected its lipid output to a physiological process (steroidogenesis) in prostate cancer.

   Evidence In vitro fatty acid elongation assay, lipidomic fatty acid composition analysis, and siRNA knockdown with androgen synthesis readout in prostate cancer cells

   PMID:19826053

   Open questions at the time

   • No structural model of the elongase or catalytic mechanism
   • Substrate-selectivity determinants for C20+ saturated VLCFAs not defined
   • SREBP1 regulation inferred from expression/pathway analysis rather than direct promoter occupancy
2. 2019 Medium

   Showed that ELOVL7 substrate preference is tissue-dependent, elongating unsaturated C16–C18 species in mammary epithelium rather than the saturated VLCFAs seen in prostate cells.

   Evidence Overexpression and knockdown in goat mammary epithelial cells with fatty acid profiling and elongation index calculation

   PMID:31242694

   Open questions at the time

   • Mechanism dictating saturated vs unsaturated substrate selection unknown
   • Cross-species relevance to human ELOVL7 not established
3. 2023 Medium

   Placed ELOVL7 within innate immune and inflammatory signaling by defining the transcriptional input (NF-κB, not STAT1) and a functional cytokine output in macrophages.

   Evidence RNA-seq, NF-κB/STAT1 pharmacological inhibitor epistasis, siRNA knockdown, and cytokine ELISA in THP-1-derived macrophages; RNA-seq of TLR7/9-stimulated pDCs

   PMID:37251958

   Open questions at the time

   • Which lipid product mediates the cytokine effect is unresolved
   • pDC induction is a single RNA-seq observation without functional follow-up
   • Direct NF-κB binding to the ELOVL7 locus not shown
4. 2025 High

   Linked ELOVL7 elongase activity to a specific cell-death mechanism, showing its LC-PUFA-phospholipid output sensitizes podocytes to ferroptosis in vivo.

   Evidence snRNA-seq, targeted lipidomics, podocyte-specific Elovl7 knockout mice, knockdown cell lines, and ferroptosis scoring

   PMID:41285716

   Open questions at the time

   • Whether the same ferroptosis-sensitizing role operates in non-podocyte tissues is untested
   • Coupling between ELOVL7 product and peroxidation machinery not mechanistically dissected
5. 2025 High

   Defined ELOVL7 as a downstream effector node of a metabolite-controlled SREBP axis in pathological cardiac remodeling, with causal rescue establishing directionality.

   Evidence Cardiomyocyte-specific FH overexpression (AAV9), TAC model, RNA-seq, metabolomics, SREBP knockdown, and Elovl7 overexpression rescue in mice

   PMID:40940503

   Open questions at the time

   • Which ELOVL7 lipid products drive cardiac hypertrophy not identified
   • Mechanism by which malate/FH modulates SREBP activity toward ELOVL7 not fully resolved

• How a single elongase's product spectrum is redirected across tissues (saturated VLCFA vs LC-PUFA vs unsaturated C16–C18) to produce divergent outcomes — steroidogenesis, ferroptosis, inflammation, cardiac remodeling — remains unresolved.
• No unifying model linking substrate selection to downstream phenotype
• No structural or regulatory basis for context-dependent specificity